A ground-breaking system to select the most viable embryos for successful IVF pregnancy.
Carmel-Diagnostics has successfully developed and patented an innovative noninvasive embryo selection system for the IVF market. Embryo viability assessment that significantly reduces the risk of multiple births by decreasing the number of transferred pre-embryos per cycle of IVF, enabling Single Embryo Transfer. The Fertissimo TCL analyzer will obtain CE Mark and FDA approval during 2018.
Successful clinical trials have been performed in Europe (Spain), and the device has been well received by the medical community, with more trials pending completion in Europe and the US.
Carmel Diagnostics has a strong and established management team with significant experience in the gynecological sector.
Carmel Diagnostics received endorsement by winning Phase-1 and Phase-2 of Horizon2020 SME Instrument, securing a grant of 2.7M€, as well as winning GFI (Grant For Fertility Innovation) by Merck Serono. Carmel’s partner for clinical validation is IVI Valencia the largest IVF clinics network in the world and most advanced in research.
Easy to use device, offering up to 20% increase in successful IVF pregnancies, compared with existing gold standard
Non-Invasive 10-minute (per embryo) analysis of embryo viability by using an improved clinical biomarker
Offers viability assessment of cryopreserved embryos and eggs
Reduced probability for Multiple pregnancy